Cardiology
RSSArticles
-
Is it time to retire niacin?
-
FDA actions
-
Rivaroxaban for atrial fibrillation patients
Rivaroxaban (Xarelto), Janssen Pharmaceutical's once-a-day oral Xa inhibitor, has been approved for reducing the risk of stroke in patients with atrial fibrillation. -
Warfarin testing every 12 weeks?
-
Adverse drug events in the elderly
-
Pharmacology Watch - Full January 2012 Issue in PDF
-
All antidepressants are created equal
-
Short course treatment for latent TB
-
Bleeding concerns with dabigatran
-
Benefits of treating systolic hypertension